CO5150206A1 - Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias - Google Patents

Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias

Info

Publication number
CO5150206A1
CO5150206A1 CO00006604A CO00006604A CO5150206A1 CO 5150206 A1 CO5150206 A1 CO 5150206A1 CO 00006604 A CO00006604 A CO 00006604A CO 00006604 A CO00006604 A CO 00006604A CO 5150206 A1 CO5150206 A1 CO 5150206A1
Authority
CO
Colombia
Prior art keywords
prevention
reduction
coronary
approximately
coronary interventions
Prior art date
Application number
CO00006604A
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey R Granett
H Shusterman Neil
Prichard David C U
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5150206A1 publication Critical patent/CO5150206A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO00006604A 1999-02-03 2000-02-03 Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias CO5150206A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11846299P 1999-02-03 1999-02-03

Publications (1)

Publication Number Publication Date
CO5150206A1 true CO5150206A1 (es) 2002-04-29

Family

ID=22378750

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00006604A CO5150206A1 (es) 1999-02-03 2000-02-03 Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias

Country Status (17)

Country Link
EP (1) EP1171116A4 (fr)
JP (1) JP2002536327A (fr)
KR (1) KR20010101934A (fr)
CN (1) CN1345237A (fr)
AU (1) AU2636600A (fr)
BR (1) BR0007921A (fr)
CA (1) CA2361581A1 (fr)
CO (1) CO5150206A1 (fr)
HK (1) HK1045104A1 (fr)
HU (1) HUP0200129A3 (fr)
IL (1) IL144721A0 (fr)
MX (1) MXPA01007835A (fr)
NO (1) NO20013788L (fr)
PL (1) PL351397A1 (fr)
TR (1) TR200102245T2 (fr)
WO (1) WO2000045811A1 (fr)
ZA (1) ZA200106353B (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617407B2 (ja) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 血管内膜細胞過剰増殖疾患の予防および治療剤
US5693337A (en) * 1994-07-13 1997-12-02 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
AU6837096A (en) * 1995-09-07 1997-03-27 Kissei Pharmaceutical Co. Ltd. 2-acylaminobenzamide derivatives and preventive and remedy for diseases caused by the supermultiplication of vascular intimal cells
US6019104A (en) * 1996-12-30 2000-02-01 Kissei Pharmaceutical Co., Ltd. Method for the treatment or prevention of restenosis associated with coronary intervention

Also Published As

Publication number Publication date
KR20010101934A (ko) 2001-11-15
ZA200106353B (en) 2002-08-02
WO2000045811A1 (fr) 2000-08-10
HUP0200129A2 (hu) 2002-05-29
TR200102245T2 (tr) 2002-05-21
PL351397A1 (en) 2003-04-07
BR0007921A (pt) 2002-09-10
MXPA01007835A (es) 2002-04-24
HUP0200129A3 (en) 2003-06-30
EP1171116A4 (fr) 2004-11-17
CN1345237A (zh) 2002-04-17
HK1045104A1 (zh) 2002-11-15
NO20013788L (no) 2001-09-28
EP1171116A1 (fr) 2002-01-16
IL144721A0 (en) 2002-06-30
CA2361581A1 (fr) 2000-08-10
JP2002536327A (ja) 2002-10-29
NO20013788D0 (no) 2001-08-02
AU2636600A (en) 2000-08-25

Similar Documents

Publication Publication Date Title
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
CR6458A (es) Composiciones de valdecoxib
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
IL139229A0 (en) Drug delivery system comprising a tightly compacted solid medicament stock
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
CA2301017A1 (fr) Utilisation de gallate de propyle pour augmenter la biodisponibilite de produits pharmaceutiques administres par voie orale
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
AU1079701A (en) Oral transmucosal drug dosage using solid solution
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
BG104797A (en) Use of dexmedetomi dine for sedative effect in patients in an intensive care unit
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
WO2001012214A3 (fr) Mofetilmycophenolate associe a peg-ifn-alpha
JP2002540148A5 (fr)
ES2115571T3 (es) Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.
CO5150206A1 (es) Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
AR025549A1 (es) Mofetil micofelonato en asociacion con peg-ifn-alfa
CO5160246A1 (es) Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)
EP1347754A4 (fr) Compositions pour la prevention d'une adherence